Evidence that vildagliptin attenuates deterioration of glycaemic control during 2‐year treatment of patients with type 2 diabetes and mild hyperglycaemia*

Abstract

In drug-naïve patients with mild hyperglycaemia, 2-year treatment with vildagliptin 50 mg once daily attenuated the progressive loss of glycaemic control seen in patients receiving only lifestyle counselling (and placebo). This appears to be because of a corresponding attenuation of the deterioration of beta-cell function as assessed by ISR/G.